HyperArc delivered stereotactic re-irradiation to 44 brain metastases after prior whole-brain RT
One patient underwent 21 Gy in three fractions to 44 recurrent brain metastases after WBRT, with rapid delivery and sustained local control.
One patient underwent 21 Gy in three fractions to 44 recurrent brain metastases after WBRT, with rapid delivery and sustained local control.
Central thoracic re-irradiation achieved 80.1% one-year local control, while cumulative esophageal V60 emerged as a potential toxicity signal.
Accelerator-based BNCT produced an 80% response and 51.1% two-year survival, but two-year local control was 31.8% with substantial toxicity.
Across 478 patients, hypofractionated proton re-irradiation showed encouraging site-specific outcomes, but heterogeneous retrospective evidence prevents firm conclusions on efficacy or safety.
Nine prospective rectal and anal re-irradiation trials varied widely in dose, margins, cumulative-dose methods, organs at risk, and PRO reporting.
Failure-free survival was 96.6% at 12 months, while grade 3 GU toxicity increased to 12.5% by one year.
A phase I study safely escalated five-fraction stereotactic boosts to 30-35 Gy after recent prior radiotherapy, with 86.5% one-year local control.
After resection of ipsilateral recurrence, five-year locoregional recurrence-free survival was 84.2%, while grade 3 late toxicity was 3.9%.
Across 12 reported patients receiving at least three radiation courses for DIPG, median survival was 27 months with frequent symptomatic benefit.
Proton hypofractionation produced 10% one-year local failure despite extensive prior irradiation, with grade 3 toxicity confined to multiply reirradiated patients.
Voxel-wise cumulative EQD2 review prompted reoptimization in 25.5% of proton reirradiation courses and exposed frequent registration problems.
In the first clinical minibeam series, 86% had symptomatic improvement and one-year local control reached 92% with minibeam treatment alone.
ESTRO supports individualized reirradiation for selected recurrent brain tumors, with cumulative dose, target volume and critical structures determining feasibility.
DIR reduced estimated liver maximum dose from 123.8 to 83.2 Gy, but accuracy deteriorated markedly for bowel and stomach.
COMPPARE enrolled 2,524 patients from 51 institutions in 52 months, with Black participation reaching 16% of the cohort.